Remote monitoring reduces heart failure hospitalizations and improves quality of life

MONITOR-HF trial presented in a late breaking science session today at Heart Failure 2023

2023-05-20

(Press-News.org) Prague, Czechia – 20 May 2023: The first investigator-initiated study of remote pulmonary artery pressure monitoring has found that it improves quality of life and reduces heart failure hospitalisations in patients with chronic heart failure. The findings are presented today in a late breaking science session at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC),1 and published in The Lancet.

Principal investigator Dr. Jasper Brugts of Erasmus University Medical Centre, Rotterdam, the Netherlands said: “Pulmonary artery pressure is a marker of haemodynamic congestion, which occurs several weeks before symptoms develop, providing a window of opportunity to prevent overt congestion and subsequent hospitalisation. In MONITOR-HF, physicians set a haemodynamic monitoring target which enabled them to provide tailored therapies such as diuretics and other medications.”

Several questions remained after two previous trials of pulmonary artery pressure monitoring in patients with chronic heart failure in North America. The CHAMPION trial, published in 2011, showed a positive result in patients with New York Heart Association (NYHA) class III heart failure, an average ejection fraction of 30%, a previous heart failure hospitalisation, and relatively low levels of background guideline-directed medical therapy.2 GUIDE-HF, published in 2021, had a neutral result in the overall analysis which may have been related to enrolling a broader and lower risk population,3 or modification by COVID-19. A pre-specified subgroup analysis limited to follow-up preceding the COVID-19 pandemic yielded a positive result.

Heart failure guidelines state that pulmonary artery pressure monitoring has uncertain value but may be considered (level IIb);4,5 uptake in Europe is therefore marginal. European data were needed comparing pulmonary artery pressure monitoring to standard of care with high levels of background medical therapy. MONITOR-HF tested the effect of haemodynamic monitoring on quality of life and heart failure hospitalisations against contemporary standard of care in the Netherlands.6

The trial enrolled 348 patients from 25 centres in the Netherlands. Patients had chronic heart failure, any ejection fraction, NYHA class III symptoms and a previous heart failure hospitalisation or urgent visit requiring intravenous diuretics in the past 12 months. The average age was 69 years, 25% were women, and the mean ejection fraction was 30%. Participants were randomly allocated 1:1 to pulmonary artery pressure monitoring on top of usual care or usual care alone (including access to regular lab measurements such as natriuretic peptides and yearly echocardiography). All patients were followed up for at least 12 months. The average duration of follow up was 18 months and the maximum was 48 months.

Patients in the monitoring group had a small, wireless, battery-free sensor implanted into the pulmonary artery via the femoral vein.7 A pressure measurement was taken every morning in about 18 seconds and readings were sent to a secure website. Physicians accessed the data and set a target pressure for each patient which would indicate the need to review drug treatment.

The primary endpoint was the change in quality of life measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 12 months and the secondary endpoint was the number of heart failure hospitalisations and/or urgent visits requiring intravenous diuretics during follow-up.

At 12 months, the average change in the KCCQ overall summary score was +7 points in the monitoring group and -0.2 points in the usual care group, yielding a mean difference between groups of 7.1 points in favour of monitoring (p=0.013). During a mean follow-up of 1.8 years there were 117 heart failure hospitalisations or urgent visits in the monitoring group and 212 in the usual care group, which represents a 44% reduction with monitoring (hazard ratio 0.56; 95% confidence interval 0.38–0.84; p<0.01).

This treatment benefit was consistent in subgroups with an ejection fraction of ≤40% and >40%. The procedure was relatively safe and reliable with a 97.7% freedom from device or system related complications and 98.8% freedom from sensor failure during follow-up.

Dr. Brugts said: “More than 85% of participants with heart failure with reduced ejection fraction were on beta-blockers, renin-angiotensin system inhibitors and mineralocorticoid receptor antagonists. The uptake of angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose co-transporter-2 inhibitors (SGLT2) was high and increased during the course of follow-up, with 60% of controls on ARNI and 30% on SGLT2 inhibitors at 12 months. This level of treatment means that any additional benefit of pulmonary artery pressure monitoring was really on top of appropriate levels of guideline directed medical therapy.”

He concluded: “Pulmonary artery pressure monitoring showed a substantial and significant effect on quality of life and heart failure hospitalisations which is highly relevant for patients, physicians and hospitals. The principle of management by exception ensures that physicians only need to respond to patients outside their threshold window, making this an efficient method with a low time requirement.”

ENDS

Authors: ESC Press Office
Tel: +33 (0)489 872 075

Email: press@escardio.org

Follow us on Twitter @ESCardioNews

Notes to editor

Funding: MONITOR-HF trial was an investigator-initiated study funded by the innovation grant 2018 of the Dutch Ministry of Health and Health Care Institute and performed together with partners of patient councils (Harteraad), insurance companies for conditional reimbursement and the Dutch Cardiac Society. Abbott, the manufacturer of the device, was obligated to cover the CRO / study costs of the trial in this programme and had no role in any part of the study design, conduct, analyses or writing.

Disclosures: Please see the paper.

References and notes

1MONITOR-HF will be presented during the session ‘Late breaking clinical trials: Chronic HF and cardiomyopathies’ which takes place on 20 May at 16:00 CEST in Room 1.

2Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–666.

3Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398:991–1001.

4McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–3726.

5Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary. J Card Fail. 2022;28:810–830.

6Brugts JJ, Veenis JF, Radhoe SP, et al. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial. Neth Heart J. 2020;28:16–26.

7The study used the CardioMEMS HF System.

About Heart Failure 2023 & World Congress on Acute Heart Failure
Heart Failure is the annual congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
#HeartFailure2023

About the Heart Failure Association

The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists about registration for Heart Failure 2023

Heart Failure 2023 takes place 20 to 23 May at the O2 universum in Prague, Czechia and online. Explore the scientific programme.

Free registration applies to accredited press. Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy. The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid. The ESC Press Office decision is final regarding all press registration requests. END

ELSE PRESS RELEASES FROM THIS DATE:

A Spanish team presents the first pharmacological treatment able to improve cardiac function in stiff-heart syndrome

2023-05-20

Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein fibrils in the heart. Amyloid fibril deposition thickens and stiffens the heart walls, and the disease is also known as stiff-heart syndrome. The accumulation of amyloid fibrils causes heart failure, and patients suffer from fluid retention, fatigue, and arrhythmias. The disease can be caused by genetic mutations or related to aging. Prognosis is poor, and untreated patients survive for an average of just 3 years. Now, the ...

George Dangas, MD, Ph.D., named President of Society for Cardiovascular Angiography & Interventions

2023-05-20

The Society for Cardiovascular Angiography & Interventions (SCAI) has named George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, at the Icahn School of Medicine at Mount Sinai as its new President. He was appointed on Saturday, May 20, during the closing ceremonies at the SCAI 2023 Scientific Sessions in Phoenix. He is the first Mount Sinai cardiologist to hold this position and will serve as the 46th President of SCAI. Dr. Dangas, also the Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at Icahn Mount Sinai and Chief of Cardiology ...

Forging partnerships in the Americas: Naval leaders gather at SIANC S&T Conference

2023-05-20

ARLINGTON, Va.—For Dr. Brett Seidle — the deputy assistant secretary of the Navy for Research, Development, Test and Engineering — the breakneck speed of current scientific progress and technological proliferation can be challenging, especially when the impact of new technologies on civilian and military realities transcends national borders. While giving the keynote address at the recent Specialized Inter-American Naval Conference on Science, Technology and Innovation (SIANC-ST&I) in Orlando, Florida, Seidle identified several scientific disciplines that have developed into ...

New study reveals possible future health impacts related to climate mitigation

2023-05-20

UNIVERSITY PARK, Pa. — Reduce fossil fuel use and air quality will improve, right? It might not be as straightforward as it appears, according to a Penn State-led research team. They explored almost 30,000 simulated future scenarios and found that some climate mitigation efforts could lead to harmful health impacts in certain geographic areas. Their results were published today (May 18) in Nature Sustainability. “In general, reducing fossil fuel use is good for climate mitigation and good for cleaning up the air, and the modeling studies have always found health benefits from climate mitigation,” said corresponding ...

Study finds cardiovascular risk score improves after one year of semaglutide use in patients with overweight and obesity

2023-05-20

New research presented at this year’s European Congress on Obesity in Dublin, Ireland shows that patients treated with the obesity drug semaglutide have a decreased cardiovascular risk score after one year of use. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues. Obesity is a major risk factor for the development of abnormal blood fat levels, type-2 diabetes mellitus (T2DM), high blood pressure, and obstructive sleep apnoea. These comorbidities are associated with an increased risk of cardiovascular disease (CVD) that represents ...

Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study

2023-05-20

New research presented at this year’s European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the most recently FDA-approved anti-obesity medication. It has shown significant weight loss outcomes in multiple long-term randomised clinical trials and short-term real-world studies. However, little is known about ...

Consequences of uncontrolled hunger in teenagers living with obesity examined in international study

2023-05-20

Teenagers living with obesity who say hunger is preventing them from losing weight (hunger-barrier ALwO) perceive their weight more negatively and worry about it more than youngsters who don’t see hunger as an obstacle, new research being presented at the European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) shows. The international study also found that hunger-barrier ALwO are more likely to be female and more likely to say their weight makes them unhappy and leads to them being bullied. They are also more likely to be actively trying to lose weight. Dr Bassam Bin-Abbas, of the Department of Paediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, ...

Stress hormone measured in hair predicts who is likely to suffer from cardiovascular diseases

2023-05-20

New research being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) suggests that glucocorticoid levels (a class of steroid hormones secreted as a response to stress) present in the hair of individuals may indicate which of them are more likely to suffer from cardiovascular diseases (CVD) in the future. “There is a tremendous amount of evidence that chronic stress is a serious factor in determining overall health. Now our findings indicate that people with higher long-term hair glucocorticoid ...

New high risk, high reward studies will tackle key unanswered questions about our planet

2023-05-20

NERC has invested £25 million in a host of high risk, high reward research projects to tackle critical environment challenges. The 44 projects cover the full spectrum of environmental science including geology, atmospheric science, biodiversity and ecology. The research will, for example: improve our understanding of volcanic activity such as eruptions a lava flows age the Earth’s solid inner core investigate historic mass extinction events predict future changes to carbon ...

A toddler’s gut bacteria predict whether they will be overweight at 5 years old

2023-05-20

The make-up and volume of gut bacteria in toddlers at 3.5 years old is predictive of body mass index (BMI) at age 5, irrespective of whether they are born prematurely or not, according to new research, being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May). The findings also identified differences in the bacteria that colonise the gut seen in adults living with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity begin in early childhood. The make-up of the gut microbiota grows and changes in the first few months and years of life and ...

Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology

Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility

Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity

[Press-News.org] Remote monitoring reduces heart failure hospitalizations and improves quality of life
MONITOR-HF trial presented in a late breaking science session today at Heart Failure 2023

Remote monitoring reduces heart failure hospitalizations and improves quality of life

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: